Platelet-activating factor augments lipopolysaccharide-induced nitric oxide formation by rat Kupffer cells

Hepatology

Volumn 23, Issue 6, 1996, Pages 1622-1630

  Mustafa, Shamimunisa B ^a   Howard, Katherine M ^a   Olson, Merle S ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; CYCLOHEXIMIDE; DACTINOMYCIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME INDUCTION; GENE EXPRESSION; GENE INDUCTION; KUPFFER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; SEPTIC SHOCK;

EID: 0029894285     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v23.pm0008675186     Document Type: Article

References (15)

1. Korbut R, Warner TD, Gryglewski RJ, Vane JR. The effect of nitric oxide synthase inhibition on the plasma fibrinolytic system in septic shock in rats. Br J Pharmacol 1994;112:289-297.
2. Lefer AM. Significance of lipid mediators in shock states. Circ Shock 1989;27:3-12.
3. Terashita Z, Imura Y, Nishikawa K, Sumida S. Is platelet activating factor (PAF) a mediator of endotoxic shock. Eur J Pharmacol 1985;109:257-261.
4. Chang SW, Fedderson CO, Henson PM, Voelkel NF. Platelet activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 1987;81:1498-1509.
5. Braquet P, Touqui L, Shen T, Vargaftig BB. Perspectives in platelet activating research. Pharmacol Rev 1987;39:97-145.
6. Snyder F. Platelet activating factor and related acetylated lipids as biologically active mediators. Am J Physiol 1990;259:c697-c708.
7. Szabó C, Wu C, Milchell JA, Gross SS, Thiemermann C, Vane JR. Platelet activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res 1993;73:991-998.
8. Bessin P, Bonner J, Souland C, Desgranxl, Pelas I, Benveniste J. Acute circulatory collapse caused by platelet activating factor in dogs. Eur J Pharmacol 1989;86:403-413.
9. Siren AL, Feuerstein G. Effects of PAF and BN 52021 on cardiac function and regional blood flow in conscious rats. Am J Physiol 1989;257:H25-H32.
10. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43: 109-142.
11. Moncada S, Higgs A. The L-arginine nitric oxide pathway. N Engl J Med 1993;329:2002-2010.
12. Lowenstein CJ, Glatt CS, Bredt DS, Snyder SH. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proc Natl Acid Sci U S A 1992;89:6711-6720.
13. Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem 1993;268:12231-12234.
14. Koide M, Kawahara Y, Nackayama I, Tsuda T, Yokoyama M. cAMP-elevating agents induce an inducible type of nitric oxide synthase in cultured vascular smooth muscle cells. J Biol Chem 1993;268:2459-24966.
15. Mühl H, Kunz D, Pfeishifter J. Expression of nitric oxide synthase in rat glomerular mesangial cells mediated by cAMP. Br J Pharmacol 1994;105:1-8.